이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

조기 미만성 피부 전신 경화증에서 체외 광분리술

미만성 피부 전신 경화증에서 ECP의 효과

The purpose of this study is to assess feasibility, safety and preliminary efficacy of Extracorporeal Photopheresis in the treatment of active diffuse cutaneous systemic sclerosis (dcSSc). This pilot study will help to determine if further study (a RCT) is justified.

연구 개요

상세 설명

Systemic sclerosis (SSc, Scleroderma) is a multisystem autoimmune disease characterized by widespread vascular injury and progressive fibrosis of the skin and internal organs. There is no effective treatment for the majority of patients with diffuse scleroderma (diffuse cutaneous systemic sclerosis; dcSSc). Only few therapies have shown modest benefits in regard to some specific organ pathologies. In the early stage of dcSSc, it may be possible to reverse inflammation and reduce the probability of irreversible fibrosis via significant immune modulation as later, often the fibrosis doesn't improve with treatment.

This is a pilot study that will treat 15 participants with dcSSc who meet the eligibility criteria. The objective of the study is to determine if the benefit of Extracorporeal photopheresis (ECP) and safety are favorable in order to consider and help in the design of a randomized controlled trial (RCT). This is a Phase II study that is uncontrolled and patients will remain on their background immunosuppressive treatment unless if contraindicated for safety or drug interactions. The trial is powered to show a mean change in skin thickness measured with modified Rodnan skin score (mRSS) of ≥5 over one year, in an uncontrolled, unblinded study. The Health Assessment Questionnaire Disability Index (HAQ-DI), patient and physician global scores, inflammatory markers, and combined response index in SSc (CRISS) will all be exploratory outcomes. Other outcomes such as changes in cells on skin biopsies from baseline to end of the trial will be explored if the study is positive.

연구 유형

중재적

등록 (추정된)

15

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Ontario
      • London, Ontario, 캐나다, N6A4V2
        • 모병
        • Rheumatology Clinic, St. Joseph's Health Care
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Patients with SSc, aged 18 years or older, and:
  2. Subjects must meet the ACR/EULAR classification criteria for SSc (2013).
  3. Early dcSSc (within 5 years of first non-Raynaud's phenomenon symptom) or any other dcSSc patients who have at least one of the signs of disease activity: mRSS of 15 or more, presence of tendon friction rubs, elevated inflammatory markers thought to be due to active dcSSc and not related to other issues such as infection or ILD with FVC% predicted <80% or HRCT showing ILD thought to be from SSc.
  4. Able to give informed consent.

Exclusion Criteria:

  1. Poor pulmonary function (FVC<40% and/or DLCO<30%).
  2. Class IV PAH or PH.
  3. Clinically significant cardiac disease.
  4. Significant concurrent, uncontrolled medical condition including, but not limited to, renal, cardiac, hepatic, pancreatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease; and cancer (i.e. co-existing melanoma, basal cell, or squamous cell skin carcinoma).
  5. Chronic or ongoing active infectious disease requiring systemic treatment, including active tuberculosis (TB) infection.
  6. Seropositivity for human immunodeficiency virus (HIV) at study entry.
  7. Active viral infection with viral replication of hepatitis B or C virus at study entry.
  8. Thrombophilia.
  9. Contraindications to heparin including history of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITTS), history of thrombocytopenia with pentosan polysulfate, known hypersensitivity to heparin or pork products.
  10. Low Platelet count (less than 100,000 per mm3).
  11. Aphakia (absence or loss of the eye's lens and has not been replaced with an artificial lens), because of the significantly increased risk of retinal damage due to the absence of lenses.
  12. Severe anemia (hemoglobin <70g/L).
  13. High white blood cell count (greater than 25000 mm3).
  14. A history of surgical spleen removal.
  15. A history of a light sensitive disease state, i.e. lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum and albinism.
  16. Previous idiosyncratic reactions to psoralen compounds.
  17. Patients who are using photosensitizing drugs such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.
  18. Treatment with more than 2 immunosuppressants (including mofetil mycophenolate, methotrexate, cyclophosphamide, biologics) at study entry.
  19. Pregnancy, breast feeding or child bearing potential without practicing highly effective contraception (and partners for men in the study).
  20. Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder).
  21. Participation in another clinical trial within six weeks before randomization in this study.
  22. Previous use of Extracorporeal photopheresis.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Administration of Extracorporeal Photopheresis Treatment

Duration of treatment: 48 weeks. Treatments occur on 2 consecutive days every 4 weeks.

Dose of UVADEX: Treatment Volume x 0.017 = mL of UVADEX for each treatment Treatment Volume (TV) is defined as: The total volume of Buffy Coat plus prime solution that will undergo photoactivation.

Route of administration: Extracorporeal

Drug Intervention using a medical device. The ECP device is already licensed in Canada. License No.7703. ECP treatment, using the drug UVADEX, will be given on 2 consecutive days every 4 weeks for a total of 26 treatment days (48 weeks).

다른 이름들:
  • ECP
  • 8걸레

The phase II aspect of the study refers to the drug, methoxsalen. Methoxsalen is being used off label from the currently approved indications in the monograph. The study is proposing to use methoxsalen in combination with with extracorporeal photopheresis for the treatment of diffuse cutaneous systemic sclerosis. Treatment will be given in addition to standard of care medications for SSc.

다른 이름들:
  • 8걸레

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in skin thickness measured by modified Rodnan Skin Score
기간: 48 weeks

modified Rodnan Skin Score (mRSS): is a standard outcome measure for skin disease in SSc and calculated by measuring skin thickness in 17 different body sites (each site scored 0-3, with a total possible additive score of 51). A higher skin score (or a higher "skin thickness") and progression of this score, is predictive of internal organ involvement and mortality. While a lower or improving (lessening) score is associated with favorable outcomes, including better survival.

48 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Change in the modified Rodnan Skin Score
기간: 12, 24 and 36 weeks

modified Rodnan Skin Score (mRSS): is a standard outcome measure for skin disease in SSc and calculated by measuring skin thickness in 17 different body sites (each site scored 0-3, with a total possible additive score of 51). A higher skin score (or a higher "skin thickness") and progression of this score, is predictive of internal organ involvement and mortality. While a lower or improving (lessening) score is associated with favorable outcomes, including better survival.

12, 24 and 36 weeks
Combined Response Index in diffuse cutaneous systemic sclerosis score
기간: 24 weeks

CRISS score: It is calculated according to changes from the start of a study, compared to an endpoint, by using the modified Rodnan Skin Score (mRSS), the Health Assessment Questionnaire - Disability Index (HAQ-DI), patient and physician global assessment of scleroderma-related health, and forced vital capacity. A CRISS score of ≥ 0.6 indicates likelihood that a patient improved on treatment.

Will be calculated with baseline data and to define disease progression at 6 months.

24 weeks
Change in Forced Vital Capacity
기간: 6 and 12 months

Change in Pulmonary Function as measured by percentage of Improving or worsening FVC.

The FVC (Forced vital Capacity) is the total amount of air exhaled during the FEV (Forced expiratory volume) test.

6 and 12 months
Change in the diffusing capacity for carbon monoxide
기간: 6 and 12 months

Change in Pulmonary Function as measured by percentage of Improving or worsening DLCO.

The DLCO (diffusing capacity of the lungs for carbon monoxide) measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in pulmonary capillaries.

6 and 12 months
Change in physician global assessment of disease activity
기간: 12, 24, 36 and 48 weeks

Measured on a Visual Analogue Scale (VAS) from 0-10, with 0 being no disease activity and 10 being the worst possible disease activity.

12, 24, 36 and 48 weeks
Change in physician global assessment of disease severity
기간: 12, 24, 36 and 48 weeks

Measured on a Visual Analogue Scale (VAS) from 0-10, with 0 being no disease severity and 10 being the worst possible disease severity.

12, 24, 36 and 48 weeks
Change in physician global assessment of disease damage
기간: 12, 24, 36 and 48 weeks

Measured on a Visual Analogue Scale (VAS) from 0-10, with 0 being no disease damage and 10 being the worst possible disease damage.

12, 24, 36 and 48 weeks
Change in patient global assessment of health status
기간: 12, 24, 36 and 48 weeks

Measured on a Visual Analogue Scale (VAS) from 0-100, with 0 being no overall effect of disease on participant, and 100 being the worst possible overall effect of disease on participant.

This is a patient reported outcome.

12, 24, 36 and 48 weeks
Change in Scleroderma Health Assessment Questionnaire
기간: 12, 24, 36 and 48 weeks

The SHAQ combines the disability and pain scales of the HAQ (HAQ-DI), with five scleroderma-specific Visual Analogue Scales for: digital ulcers, Raynaud's phenomenon, gastrointestinal (GI) symptoms, lung symptoms, and overall disease severity.

The HAQ-DI yields a score of 0-3, that indicates the extent of the respondent's functional limitations.

Each VAS score is scaled from 0 to 3, with 0 being no symptoms and 3 being the worst possible symptom severity.

A composite VAS score is not created nor are the individual VAS scores incorporated into the HAQ DI score. Typically, each VAS score is reported individually. There is a proposed way to obtain a combined score obtained by pooling the 8 domains of the HAQ DI and the 5 VASs; however, this approach has not yet been widely accepted.

This is a patient reported outcome.

12, 24, 36 and 48 weeks
Change in serum concentrations C-Reactive Protein
기간: 12, 24, 36 and 48 weeks

Change in serum concentrations of the acute phase reactant, CRP

CRP aids in the evaluation of stress, trauma, infection, inflammation, surgery & associated diseases. Blood levels of C-Reactive Protein (CRP) are known to rise in acute disease to a level of up to 50 mg/L in the presence of slight to moderate inflammatory process. Values >50 mg/L indicate high and extensive inflammatory activity.

12, 24, 36 and 48 weeks
Change in serum concentrations of Erythrocyte Sedimentation Rate
기간: 12, 24, 36 and 48 weeks

Change in serum concentrations of the acute phase reactant, ESR

Reference ranges:

Male: 0-10 mm/h Female: 0-20 mm/h

A faster-than-normal rate may indicate inflammation in the body. Inflammation is part of the immune response system. The higher the number, the higher the likelihood of inflammation.

12, 24, 36 and 48 weeks

기타 결과 측정

결과 측정
측정값 설명
기간
감염성 합병증
기간: 최대 48주까지의 치료 기간과 치료 후 최대 1개월 동안 평가
최대 48주까지의 치료 기간과 치료 후 최대 1개월 동안 평가
Regimen-related toxicities
기간: assessed for duration of treatment up to 48 weeks, and up to 12 weeks post-treatment

Adverse Events (AEs) >= Grade 3 and assessed by the investigator as 1 of the following: related or unrelated to treatment

assessed for duration of treatment up to 48 weeks, and up to 12 weeks post-treatment
Change in peripheral levels of T-cell activation marker - sIL-2R
기간: 12, 24, 36 and 48 weeks

interleukin 2 receptor (sIL-2R)

Serum sIL-2R level is a sensitive and quantitative marker of circulating peripheral blood mononuclear cell activation.

Normal range of serum sIL-2R is below 2500 pg/ml. High levels may be found in conditions associated with T-cell activation.

12, 24, 36 and 48 weeks
Change in peripheral levels of fibrillogenesis - amino terminal propeptide of type III collagen
기간: 12, 24, 36 and 48 weeks

Amino-terminal propeptide of procollagen type III (PIIINP) is generated during the synthesis of type III collagen. PIIINP is a non-specific marker of soft tissue injury.

PIIINP in serum has been shown to correlate with fibrillogenesis, and thus to be a potential direct marker of type III collagen deposition.

PIIINP reference range Adult (>19 years): 1.2 - 4.2 ug/L

12, 24, 36 and 48 weeks
Change in CD3-positive cell count (T-cell marker) in skin biopsies of involved forearm skin
기간: 24 and 48 weeks

Measured by immunohistochemistry (IHC) as the percentage of CD3-positive cells per total number of cells/mm2.

Reference rage not established (there is no range, we are looking for a stat significant change (decrease) from baseline)

24 and 48 weeks
Change in myofibroblast count in skin biopsies of involved forearm skin
기간: 24 and 48 weeks

Myofibroblasts are cells involved in the inflammatory response to injury. Myofibroblasts play an active role in collagen synthesis, and correlate with clinical measures of disease activity in SSc.

Measured by immunohistochemistry (IHC) as the percentage of alpha-SMA-positive cells per total number of cells/mm2.

Reference range not established

24 and 48 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

협력자

수사관

  • 수석 연구원: Dr. Janet E Pope, MD PhD, University of Western Ontario, Division of Rheumatology, St. Joseph's Health Care, London, Ontario, Canada

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 5월 14일

기본 완료 (추정된)

2028년 7월 1일

연구 완료 (추정된)

2029년 7월 1일

연구 등록 날짜

최초 제출

2021년 6월 1일

QC 기준을 충족하는 최초 제출

2021년 7월 22일

처음 게시됨 (실제)

2021년 8월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다